PODD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Insulet Corp (PODD) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has demonstrated solid financial growth and insider buying activity, the technical indicators and analyst sentiment suggest caution due to competitive pressures and recent price target reductions. The stock's pre-market performance and lack of strong proprietary trading signals further support a hold recommendation.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 54.988, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 253.147, with key support at 238.6 and resistance at 267.694. These mixed signals suggest no clear entry point.
Strong Q4 financial performance with 31.18% YoY revenue growth and 6.47% YoY EPS growth.
Insider buying activity has increased significantly (409.88% over the last month).
Analysts highlight the company's leading position in the insulin pump market and potential for continued adoption in Type 1 and Type 2 diabetes markets.
Analysts have broadly reduced price targets, citing competitive pressures and concerns about pricing in the pharmacy channel.
The stock has underperformed recently, and sentiment appears bearish despite strong fundamentals.
No recent news or significant events to act as a positive catalyst.
In Q4 2025, the company reported revenue growth of 31.18% YoY to $783.8M, net income growth of 0.89% YoY to $101.6M, and EPS growth of 6.47% YoY to $1.48. Gross margin improved slightly to 72.54%. The financials indicate strong top-line growth, but net income and EPS growth are relatively modest.
Analysts remain generally positive on Insulet, with multiple firms maintaining Buy or Outperform ratings. However, all firms have reduced their price targets, reflecting concerns about competitive dynamics and pricing pressures. The average price target remains significantly above the current price, but the reductions signal caution.
